802 related articles for article (PubMed ID: 17189398)
21. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
22. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
23. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
Amato R; Zhai J; Willis J; Saxena S; DeFoe M
Clin Genitourin Cancer; 2012 Sep; 10(3):153-8. PubMed ID: 22551785
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
27. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Motzer RJ; Escudier B; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Figlin RA; Hollaender N; Kay A; Ravaud A;
Cancer; 2010 Sep; 116(18):4256-65. PubMed ID: 20549832
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
30. Experience with sorafenib and adverse event management.
Bellmunt J; Eisen T; Fishman M; Quinn D
Crit Rev Oncol Hematol; 2011 Apr; 78(1):24-32. PubMed ID: 20399677
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib.
Hahn O; Stadler W
Curr Opin Oncol; 2006 Nov; 18(6):615-21. PubMed ID: 16988583
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M
Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824
[TBL] [Abstract][Full Text] [Related]
34. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
Bukowski R; Cella D; Gondek K; Escudier B;
Am J Clin Oncol; 2007 Jun; 30(3):220-7. PubMed ID: 17551296
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
37. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Bianchi G; Loibl S; Zamagni C; Salvagni S; Raab G; Siena S; Laferriere N; Peña C; Lathia C; Bergamini L; Gianni L
Anticancer Drugs; 2009 Aug; 20(7):616-24. PubMed ID: 19739318
[TBL] [Abstract][Full Text] [Related]
38. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
39. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib: new drug. Second-line treatment of kidney cancer: better evaluated than sunitinib.
Prescrire Int; 2007 Aug; 16(90):141-3. PubMed ID: 17724834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
